Nurix Therapeutics reports Q3 2026 revenue $673.1M, net income $549.8M and $1.1B cash

Nurix Therapeutics reported Q3 2026 revenue of $673.1M, net income of $549.8M, and $1.1B in cash, driven by a $653.2M license payment from Roche. R&D spending decreased slightly, while G&A rose due to transaction costs. The company advanced clinical programs for bexobrutideg and NX-5948, and presented updated clinical data at EHA 2026.

Original reporting
Published Oct 13, 2026, 10:23 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 10:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Nurix Therapeutics reports Q3 2026 revenue $673.1M, net income $549.8M and $1.1B cash — source image
Decision brief

The 30-second read

$NRIXBullishHigh
01

Why it matters

The earnings beat and cash infusion are likely to drive short‑term buying pressure, though investors should monitor pipeline execution.

02

Market read

The surprise earnings and large partnership payment make this a high‑impact news item for NRIX and potentially for peers in the biotech space.

03

What to watch

Potential regulatory or clinical trial setbacks for other pipeline assets could temper enthusiasm.

Relevance 8/10Novelty 8/10Timing: post‑earnings release today

Background

Nurix Therapeutics (NRIX) reported its Q3 2026 results, highlighting a massive license payment from Roche and a cash position exceeding $1B.

Company-level read

Ticker impact

$NRIXBullishHigh confidence
Context

Nurix Therapeutics disclosed Q3 2026 revenue of $673.1M and net income of $549.8M, driven by a $653.2M Roche license payment.

Expected impact

upward pressure as investors price in the large license payment and profit swing.

Evidence & confidence

The earnings beat prior year by orders of magnitude and include a multi‑hundred‑million cash inflow, a material catalyst for short‑term buying.

Market effects

Biotech sector may see broader uplift from a high‑margin partnership model.

US biotech investors likely react positively; limited global spillover.

Modest, confined to biotech and pharma partnership dynamics.

Counterpoint

Some investors may question sustainability of one‑off license revenue and look for longer‑term pipeline risk.

Key entities

  • Nurix Therapeutics

    Biotech firm reporting Q3 2026 earnings.

  • Roche

    Provided a $653.2M license payment to Nurix.

Related articles

Med

Nurix Therapeutics stock is up, what you need to know

Nurix Therapeutics (NRIX) shares rose 3.4% after appointing Dr. Arati V. Rao as chief medical officer. Dr. Rao will oversee clinical development, including the BTK degrader bexobrutideg partnered with Roche. The stock closed at $16.33, up 2.8% from the previous close. Nurix has faced volatility, including a 39.8% drop last week due to Sanofi ending a Phase 1 study. The company has $1.1B in cash, funding operations into 2029.

$NRIXHighAI 8/10

StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate

Nurix Therapeutics (NRIX) shares fell 38% after Sanofi (SNY) terminated development of a key Phase I immunology candidate, SAR448272 (NX-3911), under their collaboration. Despite this, the rest of the collaboration remains intact, and Nurix maintains a strong cash position. Analysts note Nurix's potential in the oral protein degrader space, particularly its partnership with Roche (RO) for bexobrutideg (NX-5948), which targets a $48B market opportunity across five diseases.

$NRIXMedAI 8/10

Nurix to present bexobrutideg data at ASH meeting

Nurix Therapeutics (NASDAQ:NRIX) will present Phase 1a/1b study data for bexobrutideg at the ASH meeting in December 2026. The data shows clinical activity and tolerability at 600 mg daily. The drug is being developed with Roche for treating relapsed/refractory CLL and SLL. Nurix is also conducting multiple clinical trials, including Phase 2 and 3 studies.